Charlotte Bradbury

University of Pittsburgh — United States

Medicine · Health Sciences

33h-index5.6kcitations118works4.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Platelet Disorders and Treatments(39), COVID-19 Clinical Research Studies(21), Venous Thromboembolism Diagnosis and Management(21), Autoimmune Bullous Skin Diseases(15), Blood groups and transfusion(14)

Publications105 total

A multicenter, randomized, open-label study of dexamethasone versus romiplostim plus dexamethasone as first line treatment in patients with newly diagnosed immune thrombocytopenia: Interim results of rodex study
Blood·2025Open Access
Secondary analysis results from VAYHIT3, a phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy
Blood·2025
KS01.6.A INTRATUMORAL IL-12/ANTI-PD-1 ONCOLYTIC HSV1 (MVR-C5252) IS SAFE AND IMMUNOACTIVE IN RECURRENT HIGH-GRADE GLIOMA: PRELIMINARY PHASE 1 RESULTS FROM A MULTICENTER MULTISTAGE CLINICAL TRIAL
Neuro-Oncology·2025Open Access
Appropriate Management of Thrombotic Risk in Patients With Primary Immune Thrombocytopenia in the UK: A Modified Delphi Consensus
eJHaem·2025Open Access
POSTER: MDS-882 A Phase 2 Study of Ianalumab in Patients With Primary Immune Thrombocytopenia Previously Treated With at Least Two Lines of Therapy (VAYHIT3)
Clinical Lymphoma Myeloma & Leukemia·2025
MDS-882: A Phase 2 Study of Ianalumab in Patients With Primary Immune Thrombocytopenia Previously Treated With at Least Two Lines of Therapy (VAYHIT3)
Clinical Lymphoma Myeloma & Leukemia·2025
Publisher Correction: Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia
Intensive Care Medicine·2025· 1 citedOpen Access
Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial
Thorax·2025· 9 citedOpen Access
Therapeutic-dose heparin combined with antiplatelets in noncritically ill patients with COVID-19: a secondary analysis of a multiplatform randomized controlled trial
Research and Practice in Thrombosis and Haemostasis·2025Open Access
A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3
Blood·2024· 1 citedOpen Access
2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19
Journal of Thrombosis and Haemostasis·2024· 35 citedOpen Access
Real‐world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the <scp>TRAIT</scp> study
British Journal of Haematology·2024· 14 citedOpen Access
Heparin Dose Intensity and Organ Support-Free Days in Patients Hospitalized for COVID-19
JACC Advances·2024· 3 citedOpen Access
VAYHIT3: An Open-Label, Single-Arm, Phase II Trial to Evaluate the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (ITP) Previously Treated with at Least 1 Corticosteroid and 1 Thrombopoietin Receptor Agonist (TPO-RA)
Blood·2023· 4 cited
Systemic immunosuppression depletes peripheral blood regulatory B cells in patients with immune thrombocytopenia
British Journal of Haematology·2023· 4 citedOpen Access
PB0486 Effect of Age on Risk for Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis
Research and Practice in Thrombosis and Haemostasis·2023Open Access
OC 40.5 Risk of All-Cause Mortality Following Anticoagulant Cessation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-Analysis
Research and Practice in Thrombosis and Haemostasis·2023Open Access
A clinical study in order to compare the effectiveness and safety of two different treatments in patients with newly diagnosed primary immune thrombocytopenia
http://isrctn.com/·2023
PB2612: UNITED KINGDOM RETROSPECTIVE OBSERVATIONAL STUDY OF ROMIPLOSTIM AND OTHER TREATMENTS IN EARLY IMMUNE THROMBOCYTOPENIA
HemaSphere·2023Open Access
Continuation of therapeutic dose heparin for critically ill patients with COVID-19
Intensive Care Medicine·2023· 6 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Rachael Parke(14), Patrick R. Lawler(12), Bryan J. McVerry(11), Scott Berry(11), Anthony Gordon(11), Djillali Annane(9), Lindsay R. Berry(9), Marc J. M. Bonten(9), Lise J Estcourt(9), Herman Goossens(9), Cameron Green(9), Colin McArthur(9), Lennie Derde(8), Farah Al-Beidh(8), Zahra Bhimani(8), Meredith Buxton(8), Allen Cheng(8), Rashan Haniffa(8), Alisa M. Higgins(8), Elizabeth Lorenzi(8)